CORCEPT THERAPEUTICS INC Research and Development Expense
CORCEPT THERAPEUTICS INC (CORT) reported Research and Development Expense of $53.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC research and development expense for the quarter ending 2026-06-30 was $53.89M, a 10.88% decline year-over-year.
- CORCEPT THERAPEUTICS INC research and development expense for the quarter ending 2026-03-31 was $66.27M, a 9.11% increase year-over-year.
- CORCEPT THERAPEUTICS INC research and development expense for the quarter ending 2025-12-31 was $64.86M, a 7.74% decline year-over-year.
- CORCEPT THERAPEUTICS INC research and development expense for the quarter ending 2025-09-30 was $68.85M, a 16.03% increase year-over-year.
- CORCEPT THERAPEUTICS INC research and development expense for fiscal 2025 was $254.91M, a 3.25% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC research and development expense for fiscal 2024 was $246.89M, a 33.92% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC research and development expense for fiscal 2023 was $184.35M, a 40.74% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC research and development expense for fiscal 2022 was $130.99M, a 15.04% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 158 month | Research and Development Expense 161 month | Research and Development Expense 164 month | Research and Development Expense 167 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $53.89M 10-Q · filed 2026-07-29 | $120.16M 10-Q · filed 2026-07-29 | $185.01M derived: sum of 3 quarters · filed 2026-07-29 | $253.86M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $66.27M 10-Q · filed 2026-04-30 | $131.12M derived: sum of 2 quarters · filed 2026-04-30 | $199.97M derived: sum of 3 quarters · filed 2026-04-30 | $260.44M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $64.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $133.70M derived: sum of 2 quarters · filed 2026-02-24 | $194.17M derived: sum of 3 quarters · filed 2026-07-29 | $254.91M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $68.85M 10-Q · filed 2025-11-04 | $129.32M derived: sum of 2 quarters · filed 2026-07-29 | $190.05M 10-Q · filed 2025-11-04 | $260.35M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $60.47M 10-Q · filed 2026-07-29 | $121.21M 10-Q · filed 2026-07-29 | $191.51M derived: sum of 3 quarters · filed 2026-07-29 | $250.84M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $60.73M 10-Q · filed 2026-04-30 | $131.03M derived: sum of 2 quarters · filed 2026-04-30 | $190.37M derived: sum of 3 quarters · filed 2026-04-30 | $249.12M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $70.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $129.64M derived: sum of 2 quarters · filed 2026-02-24 | $188.38M derived: sum of 3 quarters · filed 2026-02-24 | $246.89M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $59.34M 10-Q · filed 2025-11-04 | $118.08M derived: sum of 2 quarters · filed 2025-11-04 | $176.59M 10-Q · filed 2025-11-04 | $231.29M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $58.74M 10-Q · filed 2025-07-31 | $117.25M 10-Q · filed 2025-07-31 | $171.96M derived: sum of 3 quarters · filed 2026-02-24 | $217.47M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $58.51M 10-Q · filed 2025-05-05 | $113.21M derived: sum of 2 quarters · filed 2026-02-24 | $158.73M derived: sum of 3 quarters · filed 2026-02-24 | $202.01M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $54.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $100.22M derived: sum of 2 quarters · filed 2026-02-24 | $143.50M derived: sum of 3 quarters · filed 2026-02-24 | $184.35M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $45.52M 10-Q · filed 2024-10-30 | $88.79M derived: sum of 2 quarters · filed 2024-10-30 | $129.65M 10-Q · filed 2024-10-30 | $166.40M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $43.28M 10-Q · filed 2024-07-29 | $84.13M 10-Q · filed 2024-07-29 | $120.88M derived: sum of 3 quarters · filed 2025-02-26 | $154.17M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $40.85M 10-Q · filed 2024-05-01 | $77.61M derived: sum of 2 quarters · filed 2025-02-26 | $110.90M derived: sum of 3 quarters · filed 2025-02-26 | $143.72M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $36.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $70.05M derived: sum of 2 quarters · filed 2025-02-26 | $102.87M derived: sum of 3 quarters · filed 2025-02-26 | $130.99M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $33.29M 10-Q · filed 2023-11-01 | $66.12M derived: sum of 2 quarters · filed 2023-11-01 | $94.24M 10-Q · filed 2023-11-01 | $122.76M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $32.83M 10-Q · filed 2023-08-02 | $60.95M 10-Q · filed 2023-08-02 | $89.46M derived: sum of 3 quarters · filed 2024-02-15 | $117.56M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $28.12M 10-Q · filed 2023-05-03 | $56.64M derived: sum of 2 quarters · filed 2024-02-15 | $84.73M derived: sum of 3 quarters · filed 2024-02-15 | $112.96M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $28.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $56.61M derived: sum of 2 quarters · filed 2024-02-15 | $84.84M derived: sum of 3 quarters · filed 2024-02-15 | $113.86M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $28.09M 10-Q · filed 2022-11-03 | $56.32M derived: sum of 2 quarters · filed 2022-11-03 | $85.34M 10-Q · filed 2022-11-03 | $113.62M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $28.23M 10-Q · filed 2022-08-04 | $57.25M 10-Q · filed 2022-08-04 | $85.53M derived: sum of 3 quarters · filed 2023-02-28 | $119.40M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $29.02M 10-Q · filed 2022-05-05 | $57.30M derived: sum of 2 quarters · filed 2023-02-28 | $91.17M derived: sum of 3 quarters · filed 2023-02-28 | $117.66M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $62.14M derived: sum of 2 quarters · filed 2023-02-28 | $88.64M derived: sum of 3 quarters · filed 2023-02-28 | $114.76M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $33.87M 10-Q · filed 2021-11-03 | $60.37M derived: sum of 2 quarters · filed 2021-11-03 | $86.49M 10-Q · filed 2021-11-03 | $110.80M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | $26.50M 10-Q · filed 2021-07-29 | $52.62M 10-Q · filed 2021-07-29 | $76.93M derived: sum of 3 quarters · filed 2022-02-15 | $99.74M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-03-31 | $26.12M 10-Q · filed 2021-05-06 | $50.44M derived: sum of 2 quarters · filed 2022-02-15 | $73.24M derived: sum of 3 quarters · filed 2022-02-15 | $94.90M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $24.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $47.12M derived: sum of 2 quarters · filed 2022-02-15 | $68.77M derived: sum of 3 quarters · filed 2022-02-15 | $89.02M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $22.80M 10-Q · filed 2020-11-03 | $44.46M derived: sum of 2 quarters · filed 2020-11-03 | $64.70M 10-Q · filed 2020-11-03 | $83.50M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-06-30 | $21.66M 10-Q · filed 2020-08-04 | $41.90M 10-Q · filed 2020-08-04 | $60.69M derived: sum of 3 quarters · filed 2021-02-23 | $79.55M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2019-03-31 | $20.24M 10-Q · filed 2020-05-04 | $39.04M derived: sum of 2 quarters · filed 2021-02-23 | $57.90M derived: sum of 3 quarters · filed 2021-02-23 | $78.44M derived: sum of 4 quarters · filed 2021-02-23 | ||||
| 2018-12-31 | $18.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $37.65M derived: sum of 2 quarters · filed 2021-02-23 | $58.20M derived: sum of 3 quarters · filed 2021-02-23 | $75.25M 10-K · filed 2021-02-23 | ||||
| 2018-09-30 | $18.86M 10-Q · filed 2019-11-07 | $39.40M derived: sum of 2 quarters · filed 2019-11-07 | $56.45M 10-Q · filed 2019-11-07 | $70.08M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $20.54M 10-Q · filed 2019-08-01 | $37.59M 10-Q · filed 2019-08-01 | $51.22M derived: sum of 3 quarters · filed 2020-02-24 | $62.92M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $17.05M 10-Q · filed 2019-05-09 | $30.68M derived: sum of 2 quarters · filed 2020-02-24 | $42.37M derived: sum of 3 quarters · filed 2020-02-24 | $50.25M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $25.32M derived: sum of 2 quarters · filed 2020-02-24 | $33.20M derived: sum of 3 quarters · filed 2020-02-24 | $40.38M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $11.69M 10-Q · filed 2018-11-02 | $19.57M derived: sum of 2 quarters · filed 2018-11-02 | $26.75M 10-Q · filed 2018-11-02 | $33.23M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | $7.88M 10-Q · filed 2018-08-09 | $15.05M 10-Q · filed 2018-08-09 | $21.54M derived: sum of 3 quarters · filed 2019-02-26 | $28.59M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $7.18M 10-Q · filed 2018-05-09 | $13.66M derived: sum of 2 quarters · filed 2019-02-26 | $20.71M derived: sum of 3 quarters · filed 2019-02-26 | $26.39M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | $6.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $13.54M derived: sum of 2 quarters · filed 2019-02-26 | $19.21M derived: sum of 3 quarters · filed 2019-02-26 | $23.84M 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $7.05M 10-Q · filed 2017-11-03 | $12.73M derived: sum of 2 quarters · filed 2017-11-03 | $17.36M 10-Q · filed 2017-11-03 | $21.45M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | $5.67M 10-Q · filed 2017-08-02 | $10.31M 10-Q · filed 2017-08-02 | $14.39M derived: sum of 3 quarters · filed 2018-02-28 | $18.01M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | $4.63M 10-Q · filed 2017-05-02 | $8.72M derived: sum of 2 quarters · filed 2018-02-28 | $12.34M derived: sum of 3 quarters · filed 2018-02-28 | $15.68M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | $4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $7.70M derived: sum of 2 quarters · filed 2018-02-28 | $11.04M derived: sum of 3 quarters · filed 2018-02-28 | $15.42M 10-K · filed 2018-02-28 | ||||
| 2015-09-30 | $3.61M 10-Q · filed 2016-11-02 | $6.95M derived: sum of 2 quarters · filed 2016-11-02 | $11.33M 10-Q · filed 2016-11-02 | $15.12M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-06-30 | $3.34M 10-Q · filed 2016-08-03 | $7.72M 10-Q · filed 2016-08-03 | $11.51M derived: sum of 3 quarters · filed 2017-03-06 | $14.55M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-03-31 | $4.38M 10-Q · filed 2016-05-04 | $8.17M derived: sum of 2 quarters · filed 2017-03-06 | $11.21M derived: sum of 3 quarters · filed 2017-03-06 | $15.46M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2014-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $6.84M derived: sum of 2 quarters · filed 2017-03-06 | $11.09M derived: sum of 3 quarters · filed 2017-03-06 | $18.37M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $3.05M 10-Q · filed 2015-11-06 | $7.30M derived: sum of 2 quarters · filed 2015-11-06 | $14.58M 10-Q · filed 2015-11-06 | $21.15M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2014-06-30 | $4.25M 10-Q · filed 2015-08-07 | $11.54M 10-Q · filed 2015-08-07 | $18.10M derived: sum of 3 quarters · filed 2016-03-10 | $23.26M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2014-03-31 | $7.29M 10-Q · filed 2015-05-08 | $13.85M derived: sum of 2 quarters · filed 2016-03-10 | $19.01M derived: sum of 3 quarters · filed 2016-03-10 | $23.50M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2013-12-31 | $6.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $11.72M derived: sum of 2 quarters · filed 2016-03-10 | $16.21M derived: sum of 3 quarters · filed 2016-03-10 | $20.47M 10-K · filed 2016-03-10 | ||||
| 2013-09-30 | $5.16M 10-Q · filed 2014-11-07 | $9.65M derived: sum of 2 quarters · filed 2014-11-07 | $13.90M 10-Q · filed 2014-11-07 | $18.76M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2013-06-30 | $4.49M 10-Q · filed 2014-08-08 | $8.75M 10-Q · filed 2014-08-08 | $13.60M derived: sum of 3 quarters · filed 2015-03-13 | $16.61M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2013-03-31 | $4.26M 10-Q · filed 2014-05-12 | $9.11M derived: sum of 2 quarters · filed 2015-03-13 | $12.12M derived: sum of 3 quarters · filed 2015-03-13 | $14.79M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2012-12-31 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $7.86M derived: sum of 2 quarters · filed 2015-03-13 | $10.53M derived: sum of 3 quarters · filed 2015-03-13 | $14.07M 10-K · filed 2015-03-13 | ||||
| 2012-09-30 | $3.01M 10-Q · filed 2013-11-12 | $5.68M derived: sum of 2 quarters · filed 2013-11-12 | $9.22M 10-Q · filed 2013-11-12 | $15.86M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-06-30 | $2.67M 10-Q · filed 2013-08-09 | $6.21M 10-Q · filed 2013-08-09 | $12.86M derived: sum of 3 quarters · filed 2014-03-14 | $16.08M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-03-31 | $3.54M 10-Q · filed 2013-05-08 | $10.19M derived: sum of 2 quarters · filed 2014-03-14 | $13.42M derived: sum of 3 quarters · filed 2014-03-14 | $19.62M derived: sum of 4 quarters · filed 2014-03-14 | $157.70M 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $9.87M derived: sum of 2 quarters · filed 2014-03-14 | $16.08M derived: sum of 3 quarters · filed 2014-03-14 | $21.00M 10-K · filed 2014-03-14 | $154.16M 10-K · filed 2012-03-13 | |||
| 2011-09-30 | $3.23M 10-Q · filed 2012-11-08 | $9.43M derived: sum of 2 quarters · filed 2012-11-08 | $14.36M 10-Q · filed 2012-11-08 | $19.02M derived: sum of 4 quarters · filed 2013-03-15 | $147.52M 10-Q · filed 2011-11-08 | |||
| 2011-06-30 | $6.20M 10-Q · filed 2012-08-09 | $11.13M 10-Q · filed 2012-08-09 | $15.79M derived: sum of 3 quarters · filed 2013-03-15 | $21.01M derived: sum of 4 quarters · filed 2013-03-15 | $144.29M 10-Q · filed 2011-08-09 | |||
| 2011-03-31 | $4.92M 10-Q · filed 2012-05-10 | $9.59M derived: sum of 2 quarters · filed 2013-03-15 | $14.81M derived: sum of 3 quarters · filed 2013-03-15 | $19.39M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2010-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $9.89M derived: sum of 2 quarters · filed 2013-03-15 | $14.46M derived: sum of 3 quarters · filed 2013-03-15 | $18.95M 10-K · filed 2013-03-15 | ||||
| 2010-09-30 | $5.22M 10-Q · filed 2011-11-08 | $9.80M derived: sum of 2 quarters · filed 2011-11-08 | $14.29M 10-Q · filed 2011-11-08 | |||||
| 2010-06-30 | $4.57M 10-Q · filed 2011-08-09 | $9.06M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $14.40M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |